Abstract
Diseases with distinctive clinical features can often be identified with occurrence in early history. Hippocrates has been credited with clinical descriptions of mumps, parotitis and orchitis in thea fifth century BC [1]. Hamilton [2] is credited with the first recognition, in 1790, of central nervous system involvement in mumps and with the first description of neuropathology in fatal cases. Johnson and Goodpasture [3, 4] provided the first definitive evidence of viral etiology in mumps through monkey and human experimentation. Cultivation of mumps virus in embryonated hens’ eggs was accomplished by Habel in 1945 [5].
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Deceased
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Cochi SL, Wharton M. Plotkin SA. Mumps vaccine. In: Plotkin SA, Mortimer ES Jr, eds. Vaccines Philadelphia: WB Saunders, 1994:277–301
Hamilton R. An account of a distemper by the common people of England vulgarly called the mumps. London med J 1790; (1) 190–211
Johnson CD, Goodpasture EW. An investigation of the etiology of mumps. J Exp Med 1934;59:1–19
Johnson CD, Goodpasture E. The etiology of mumps. Am J Hyg 1935;21:46–57
Habel K. Cultivation of mumps virus in the developing chick embryo and its application to studies of immunity to mumps in man. Public Health Rep 1945;60:201–12
Rima BK. Mumps Virus. In: Webster RG, Granoff A, eds. Encyclopedia of Virology. London: Academic Press, 1994;2:876–83
Wolinsky JS, Waxham MN. Mumps virus. In: Fields BN, Knipe DM, eds. Virology. New York: Raven Press, 1990;2nd ed:989–1011
Nussinovitch M, Volvovitz B, Varsana I. Complications of mumps requiring hospitalization in children. Eur J Pediatr 1995;154:732–4
Hilleman MR, Buynak EB, Weibel RE, Stokes J Jr. Live, attenuated mumps-virus vaccine. N Engl Med 1968;278:227–32
Hilleman MR. Past, present, and future of measles, mumps and rubella virus vaccines. Pediatrics 1992;90:149–53
Weibel RE, Buynak EB, McLean AA, Hilleman MR. Follow-up surveillance for antibody in human subjects following live attenuated measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med 1979;162:328–32
Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR. Persistance of antibody in human subjects for seven to ten years following administration of combined live attenuated measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med 1980;165:260–3
Smorodintsev AA, Klyachko NS. Mumps live vaccine in the USSR: a summary of recent developments. Prog Med Virol 1961;3:273–86
Cizman M, Mozetic M, Furman-Jakopic M, Pleterski-Rigler D, Radescek-Rakar R, Susec-Michieli M. Aseptic meningitis following combined vaccination with the Leningrad-3 strain of mumps virus and the Edmonston-Zagreb strain of measles virus. Zdrav Vestn 1986;55:587–91
Penttinen K, Cantell K, Somer P, Poikolianen A. Mumps vaccination in the Finnish defense forces. Am J Epidemiol 1968;39:363–71
Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine. I. Vaccine development. Proc Soc Exp Biol Med 1966;123:768–75
Stokes H Jr., Weibel RE, Buynak EB, Hilleman MR. Live attenuated mumps-virus vaccine. II. Early clinical studies. Pediatrics 1967;39:363–71
Weibel RE, Stokes J Jr., Buynak EB, Whitman JE Jr., Hilleman MR. Live attenuated mumps-virus vaccine 3. Clinical and serological aspects in a field evaluation. N Engl J Med 1967;276:245–51
Hilleman MR, Weibel RE, Buynak EB, Stoke J Jr., Whitman JE Jr. Live attenuated mumps-virus vaccine. 4. Protective efficacy as measured in a field evaluation. N Engl J Med 1967;276:252–8
Buynak EB, Whitman JE Jr., Roehm RR, Morton DH, Lampson GP, Hilleman MR. Comparisons of neutralization and hemagglutination-inhibition techniques for measuring mumps antibody. Proc Soc Exp Biol Med 1967;125:1068–71
Davidson WL, Buynak EB, Leagus MB, Whitman JE Jr., Hilleman MR. Vaccination of adults with live attenutatied mumps virus vaccine. JAMA 1967;201:995–8
Hilleman MR. Mumps vaccination. In: Heath RB, Waterson AP, eds. Modern Trends in Medical Virology. London: Butterworths, 1970;241–61
Buynak EB, Hilleman MR, Leagus MB, Whitman JE Jr., Weibel RE, Stokes J Jr. Jeryl Lynn strain live attenuated mumps virus vaccine: Influence of age, virus dose, lot, and γ-globulin administration on response. JAMA 1968;203:9–13
McAleer WJ, Markus HZ, McLean AA, Buynak EB, Hilleman MR. Stability on storage at various temperatures of live measles, mumps, and rubella virus vaccines in new stabilizer. J Biol Stand 1980;8:281–7
Gut JP, Lablache C, Behr S, Kim A. Symptomatic mumps virus reinfections. J Med Virol 1995;45:17–23
Hilleman MR, Stokes J Jr., Buynak EB, Weibel R, Halenda R, Goldner H. Enders’ live measles virus vaccine with human immune globulin. 2. Evaluation of efficacy. Am J Dis Child 1962;103:373–9
Hilleman MR, Buynak EB, Weibel RE, Stokes J Jr., Whitman JE Jr., Leagus MB. Development and evaluation of the Moraten measles virus vaccine. JAMA 1968;206:587–90
Rubin H. A virus in chick embryos which induces resistance in vitro to infection with rous sarcoma virus. Proc Natl Acad Sci USA 1960;46:1105–19
Hughes WF, Watanabe DH, Rubin H. The development of a chicken flock apparently free of leukosis virus. Avian Dis 1963;7:154–65
World Health Organization: Meningitis associated with measles-mumps-rubella vaccines. Weekly Epidemiological Record 1992;67:301–2
Forsey T, Bentley ML, Minor PD, Begg N. Mumps vaccines and meningitis. Lancet 1992;340:980
Miller E, Goldacri M, Pugh S et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993;341:979–82
Schmitt HJ, Just M, Neiss A. Withdrawal of a mumps vaccine: reasons and impacts. Eur J Pediatr 1993;152:387–8
Fures J. Vaccine-related mumps meningitis-Canada. Can Dis Weekly Rep 1990;16–50:253–4
Motegi Y, Fijinaga T, Tamura H, Kuroume T. A survey of children with meningitis following measles, mumps, and rubella (MMR) immunization. Pediatr Res 1990;27:95A (Abstr 558)
Yawata M. Japan’s troubles with measles-mumps-rubella vaccine. Lancet 1994;343:105–6
Sawada H, Yano S, Oka Y, Togashi T. Transmission of Urabe mumps vaccine between siblings. Lancet 1993;342:371
Afzal MA, Pickford AR, Forsey T, Heath AB, Minor PD. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates, J Gen Virol 1993;74:917–20
Künkel U, Driesel G, Henning U, Gerike E, Willers H, Schreier E. Differentiation of vaccine and wild mumps viruses by polymerase chain reaction and nucleotide sequencing of the SH gene: brief report. J Med Virol 1995;45:121–6
Hilleman MR, Weibel RE, Buynak EB, Villarejos VM. Practical aspects concerning combined live viral vaccines. Schweiz Rundschau Med (PRAXIS) 1975;64:98–108
Katz SL, Enders JF. Immunization of children with a live attenuated measles virus. Am J Dis Child 1959;98:605–7
Stokes J Jr., Weibel RE, Buynak EB, Hilleman MR. Clinical and laboratory tests of Merck strain live attenuated rubella virus vaccine. First International Conference on Vaccines against Viral and Rickettsial Diseases of Man, Washington, DC, 7–11 November 1966. Pan America Health Organization Sci Publ No 147. 1967;402–5
Buynak EB, Hilleman MR, Weibel RE, Stokes J Jr. Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing. JAMA 1968;204:195–200
Weibel RE, Stokes J Jr., Buynak EB, Whitman JE Jr., Leagus MB, Hilleman MR. Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution. JAMA 1968;205:554–8
Hilleman MR, Buynak EB, Weibel RE, Stokes J Jr. Current concepts. Live, attenuated rubella-virus vaccines. New Engl J Med 1968;279:300–3
Hilleman MR, Buynak EB, Whitman JE Jr., Weibel RE, Stokes J Jr. Summary report on rubella virus vaccines prepared in duck embryo cell culture. Symp Series Immunobiol Stand 1969;11:349–56
Weibel RE, Stokes J Jr., Buynak EB, Hillman MR. Live rubella vaccines in adults and children. HPV-77 and Merck-Benoit strains. Am J Dis Child 1969;118:226–9
Meyer HM JR., Parkman PD, Panis TC. Attenuated rubella virus. II. Production of experimental live-virus vaccine and clinical trial. N Engl J Med 1966;275:575–80
Hilleman MR, Buynak EB, Whitman JE Jr., Weibel RE, Stokes J Jr. Live attenuated rubella virus vaccines. Experiences with duck embryo cell preparations. Am J Dis Child 1969;118:166–71
Buynak EB, Larson VM, McAleer WJ, Mascoli CC, Hilleman MR. Preparation and testing of duck embryo cell culture rubella vaccine. Am J Dis Child 1969;118:347–54
Plotkin SA, Farquhar JD, Katz M, Buser F. Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am J Dis Child 1969;118:178–85
Weibel RE, Villarejos VM, Klein EB, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live attenuated RA27/3 and HPV-77-DE rubella virus vaccines. Proc Soc Exp Biol Med 1980;165:44–9
Weibel RE, Carlson AJ Jr., Villarejos VM, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA27/3 rubella virus. Proc Soc Exp Biol Med 1980;165:323–6
Weibel RE, Stokes J Jr., Villarejos VM, Arguedas GJA, Buynak EB, Hilleman MR. Combined live rubella-mumps virus vaccine. Findings in clinical-laboratory studies. JAMA 1971;216:983–6
Villarejos VM, Arguedas GJA, Buynak EB, Weibel RE, Stokes J Jr., Hilleman MR. Combined live measles-rubella virus vaccine. J Pediatr 1971;79:599–604
Buynak EB, Weibel RE, Whitman JE Jr., Stoke J Jr., Hilleman MR. Combined live measles, mumps, and rubella virus vaccines. JAMA 1969;207:2259–62
Hilleman MR, Weibel RE, Villarejos VM, et al. Combined live virus vaccines. Proceedings of the International Conference on the Application of Vaccines against Viral, Rickettsial, and Bacterial Diseases of Man, Washington DC, 14–18 December 1970. Pan American Health Organization Sci Publ No 226. 1971;397–400
Stokes J Jr., Weibel RE, Villarejos VM, Arguedas GJA, Buynak EB, Hilleman MR. Trivalent combined measles-mumps-rubella vaccine. Findings in clinical laboratory studies. JAMA 1971;218:57–61
Weibel RE, Villarejos VM, Hernández CG, Stokes J Jr., Buynak EB, Hilleman MR. Combined live measles-mumps virus vaccine. Findings in clinical-laboratory studies. Arch Dis Child 1973;48:532–6
Plotkin SA, Rubin SA. Mumps vaccines. Vaccines 2008, 5th ed. pp: 435–466. W.B. Saunders, Philadelphia
Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine 2009;27:6186–95
Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008;47:1458–67
Dominquez A, Tormer N, Castilla J, et al. Mumps vaccine effectiveness in highly immunized populations. Vaccine 2010;28:3567–70
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Hilleman, M.R. (2011). The Development of Live Attenuated Mumps Virus Vaccine in Historic Perspective and Its Role in the Evolution of Combined Measles–Mumps–Rubella. In: Plotkin, S. (eds) History of Vaccine Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1339-5_23
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1339-5_23
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1338-8
Online ISBN: 978-1-4419-1339-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)